Company / Cash & Equivalents
TransMedics Group, Inc. Cash & Equivalents History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$394.8M
FY2023
5-year range
$25.6M / $394.8M
FY2019-FY2023
Trend
+96.2%
vs FY2022
Sector context
#55 of 152
Health Care
What the data says
At $395M, TransMedics Group, Inc.'s cash & equivalents ranks #55 of 152 in the Health Care sector. Cash & Equivalents has increased for 4 consecutive years, from $20M in FY2019 to $395M in FY2023.
Based on SEC 10-K filings.
$395M in FY2023 with a 5-year CAGR of +81.1%.
Improved from $26M to $395M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +152.3%
- 5-Year CAGR
- +81.1%
- 10-Year CAGR
- -
Sector benchmark
#55 of 152 in Health CareTop 36% of 152This company $394.8M Sector average $1.2B
▼
-66.4% below sector average
Key checks
Key Insights
- TransMedics Group, Inc.'s cash & equivalents has grown for 4 consecutive years.
- 5-year CAGR of +81.1%, indicating consistent growth.
- In FY2023, cash & equivalents increased 96.2% year-over-year.
- Ranks #55 out of 152 companies in the Health Care sector.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $394.8M | +96.2% |
| FY2022 | $201.2M | +686.5% |
| FY2021 | $25.6M | +4.1% |
| FY2020 | $24.6M | +22.3% |
| FY2019 | $20.1M | -0.7% |
| FY2018 | $20.2M | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026